Last updated: 2026-10-19 21:45:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Vericel Corporation (VCEL) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $40.37, with a market capitalization of $2.05B and a P/E ratio of 84.84. Over the past 52 weeks, its price has ranged from $28.95 to $49.32. This page covers its latest market performance, valuation, price trends and company information.
$2.05B | |
$40.36 | |
$68.94 | |
$1.69 | |
$40.13 | |
248.26K | |
512.82K | |
84.84 | |
$49.32 | |
$28.95 | |
-- | |
-- |
Vericel Corporation (VCEL) is trading at $40.37 in after-hours trading as of 2026-10-19 20:40:00, up 0.60% ($0.24) from the regular-session close of $40.13.
After-hours trading shows how investors are pricing VCEL after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Vericel Corporation (VCEL) moved from $40.05 to $40.37, representing a gain of 0.80% ($0.32).
The stock traded between $39.00 and $44.05 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 560.51 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 56.1%
VCEL is currently trading at $40.37, placing it 56.1% of the way from its 52-week low of $28.95 to its 52-week high of $49.32. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 398 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vericel Corporation (VCEL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.